Questions discussed in this category

Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?

Is it at neutrophil recovery, at documentation of CR on bone marrow biopsy, or is there a different point in time?

For instance, would you discontinue when there is resolution of adenopathy and normalization of counts? If so, do you overlap ibrutinib with other the...

For instance, do you ever start with dasatinib 50 mg daily?  Are there any titration schedules that you follow?

if so, are there specific cytogenetic, molecular, clinical, or hematologic factors that you take into consideration?

Thrombosis was ruled out and no etiology was found.  Would you start ponatinib back at a lower dose, transition to omacetaxine or begin transplan...

Do you await molecular and cytogenetic results prior to initiating therapy, or does age and function status primarily drive your choice?

NCCN does not list any preferences for the TKIs in their guidelines.

FDA package insert lists posaconazole as strong cyp3A4 inhibitor and states to consider other therapies.

Does presenting total white blood cell count affect your decision? Does myeloid subtype affect your decision? 

How might your decision change if the patient had a suitable 10/10 donor? How about if the patient had a targetable molecular mutation such as IDH2?

Shanafelt et al. recently presented results from the phase III E1912 study at ASH 2018. Will you still utilize FCR as first-line or now use Ritux...

What factors influence your decision (patient/disease characteristics, additional agents added to induction chemotherapy, CR1 or later, etc)?

If a patient obtains a PR or less to front line cladribine, what factors help you chose between a second course of cladribine, an alternative pur...

When is it warranted to utilize targeted therapies for known mutations (eg. midostaurin or an alternative TKI for FLT3 mutations, ivosidenib for ...

Could one make a case for addition of Rituxinab frontline to increase the chances of a complete remission and even maybe achieve MRD-negative status ?

Technically, you can have up to 55% of larger cells circulating and still be called CLL.

Specifically, in patients that had progression or developed toxicity on ibrutinib? Idelalisib is very toxic and venetoclax a labor-intensive drug to g...

Even though Venetoclax is not FDA-approved yet, assuming you can get it off label? 1. Gemtuzumab: What dose/schedule and which HMA? 2. Venetoclax: W...

Drug information indicates a patient may need 3-4 months off TKI. This seems like a long time off drug. Would a MMR of a certain duration make it less...

Specifically, can you rechallenge after the effusion has resolved (e.g. therapeutic thoracentesis)? If so, how long do you wait to rechallenge (especi...

Imatinib, or a second-generation TKI? Are there specific factors that make you choose one over the other?

Specifically, do you just wait for count recovery? Do you check for morphologic or molecular remission at all during this time?

Do you re-challenge them?  If so, what pre-medications do you give?  Do you dose reduce the cytarabine? Or do you switch another regimen?

Would you continue ibrutinib even if they are placed on anti-platelet therapy such as clopidogrel or ticagrelor?

What is the utility of repeating FISH studies to evaluate for clonal evolution if FISH studies were done at diagnosis?  

Papers discussed in this category

Cancer, 2004-08-15

Br. J. Haematol., 2003-11-01

Br. J. Haematol., 1998-08-01

Cancer, 1990-11-15

Radiother Oncol, 1990-01-01

The New England journal of medicine, 2010-06-17

Blood, 2014-01-23

The New England journal of medicine, 2010-06-17

The New England journal of medicine, 2015-12-17

Medical and pediatric oncology, 1981

British journal of haematology, 2004-04



Br. J. Haematol., 2017 Nov 21

Blood, 2018-06-21

Nature, 2019-06

Leukemia, 2019-02

The Lancet. Oncology, 2009-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-05-15

Cancer, 2011-06-15

American journal of hematology, 2009-09

Cancer, 2010-08-15

Blood, 2013-11-14

J. Clin. Oncol., 2016 Jan 25

Leukemia, 2016-02

The Lancet. Oncology, 2018-02

Avicenna J Med, 2017 Jul-Sep

Blood, 2014-05-22

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-10

Fertil. Steril., 2013 Sep 05

Leukemia, 2018-08

The New England journal of medicine, 2015-10-29

Blood, 2017-03-09

Cancer, 2015-12-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-08-01

The New England journal of medicine, 2017-08-03

Lancet, 2012 Apr 05

Haematologica, 2018 Aug 03

Cancer, 2014-12-01

Blood, 1998-09-01

Blood, 2019-04-04

American journal of hematology, 2018-08

Am. J. Hematol., 2019 Nov 19

N. Engl. J. Med.,

Nature medicine, 2015-02

Clin Lymphoma Myeloma Leuk, 2017 Jun 21

The New England journal of medicine, 2007-01-25

Blood, 2016-07-28

Blood advances, 2016-12-27

Cancer, 2016-10

Blood, 2017-08-31

Biol. Blood Marrow Transplant., 2019 Aug 22


Blood, 2018 Apr 5

N Engl J Med,